Onco-Innovations has identified a non-tin catalyst to improve the polymer synthesis process for ONC010, its lead cancer drug candidate. This advancement enhances manufacturing consistency and quality control, supporting future large-scale production under GMP standards. The company also completed a 300-gram batch of the active ingredient with high purity and progressed preclinical studies and clinical trial preparations in Australia. These integrated developments position ONC010 for potential First-in-Human trials later in 2026.
Zoom Video Communications will release its Q3 2026 earnings on August 25, with analysts expecting $1.48 EPS and $1.27 billion revenue. Despite a slight EPS decline from last year, Zoom has a strong track record of surpassing earnings estimates in nin...
Roth Capital increased its price target for nVent Electric to $195 from $185, citing strong growth potential driven by the company's planned $1.75 billion acquisition of Maverick Power. This deal aims to expand nVent's offerings in the growing data c...
Snowflake, a leading cloud data platform, is showing strong market momentum with analysts maintaining a Buy rating and raising price targets from $290 to $360. Despite a recent 3% dip, its stock has surged over 24% in the past month, outperforming th...
Dick's Sporting Goods reported quarterly earnings with an EPS of $3.53, below the expected $3.76, and revenue that also missed Wall Street forecasts. The shortfall is partly due to the Foot Locker acquisition, which lowered EPS and led to a reduced f...
Semtech Corporation is set to report strong Q2 earnings with an expected EPS of $0.61, up from $0.41 last year, and projected revenue of $328.67 million, a 27.5% increase driven by demand in data centers and its LoRa technology. The company recently ...
